- Home
- CMMB
as 11-06-2025 3:56pm EST
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Upcoming Earnings Alert:
Get ready for potential market movements as Chemomab Therapeutics Ltd. CMMB prepares to release earnings report on 12 Nov 2025.
| Founded: | 2004 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 13.7M | IPO Year: | N/A |
| Target Price: | $26.50 | AVG Volume (30 days): | 151.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.39 - $9.84 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Chemomab Therapeutics Ltd. News
CMMB Breaking Stock News: Dive into CMMB Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Zacks
16 days ago
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Zacks
20 days ago
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Zacks
21 days ago
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
Zacks
22 days ago
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Zacks
23 days ago
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Zacks
a month ago
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Zacks
a month ago
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Compare CMMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMMB Chemomab Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.